VASFAS


Stephen Emery, MD Associate Professor of Obstetrics, Gynecology and Reproductive Sciences
Director, Center for Innovative Fetal Intervention, Magee Women's Hospital of UPMC
Email:semery@magee.edu

https://mageewomens.org/investigator/stephen-emery-md/
Stephanie Greene, MD Assistant Professor of Neurological Surgery, University of Pittsburgh School of Medicine
Director of Perinatal Neurosurgery, Children's Hospital of Pittsburgh
Email:Stephanie.Greene@chp.edu

http://www.neurosurgery.pitt.edu/person/stephanie-greene
Youngjae Chun Assistant Professor, Department of Industrial Engineering, University of Pittsburgh
Email:yjchun@pitt.edu

https://www.engineering.pitt.edu/Youngjae_Chun/

Fetal aqueductal stenosis is the leading cause of congenital hydrocephalus and effects 2-4 infants per 10,000 births. The condition can currently be diagnosed via ultrasound as early as 20 weeks of gestation. However, no treatment is available until after birth, leading to increased risks of obstetric complications for the mother and long-term complications for the child. VASFAS is a shunt that will be placed in the fetus through the maternal abdominal wall under ultrasound guidance allowing for immediate treatment of hydrocephalus in-utero. A potential market of $140 million has been estimated and no other fetal shunts for hydrocephalus treatment are currently available on the market.